REG - Genedrive PLC - Block Listing Returns

GenedriveAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA3149Ga&default-theme=true

RNS Number : 3149G  Genedrive PLC  01 June 2026

01 June 2026

 

genedrive plc

("genedrive" or the "Company")

 

Block Listing Returns

 

The Company confirms the block listing six monthly return for the period to 31 May 2026.

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  2007 Share Option Scheme
 Period of return:                       From:                                   01 December 2025  To:         31 May 2026
 Balance of unallocated securities under scheme(s) from previous return:         131,726 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      131,726 shares

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  2017 Share Option Scheme
 Period of return:                       From:                                   01 December 2025  To:         31 May 2026
 Balance of unallocated securities under scheme(s) from previous return:         1,150,588 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      1,150,588 shares

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  Unapproved Share Option Scheme
 Period of return:                       From:                                   01 December 2025  To:           31 May 2026
 Balance of unallocated securities under scheme(s) from previous return:         2,668,144 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      2,668,144 shares

 Name of contact:                                                                Russ Shaw CFO
 Telephone number of contact:                                                    +44 (0)161 989 0245

 

 

For enquires:

 

 genedrive plc
                                                        +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO
                                                        https://investors.genedrive.com/s/e0025c
                                                        (https://investors.genedrive.com/s/e0025c)

 Peel Hunt LLP (Nominated Adviser and Broker)
                                                        +44 (0)20 7418 8900
 James Steel

 5654 & Company  (Media & Investor Relations)           genedrive@5654.co.uk
 Matthew Neal                                           +44 (0)7917 800 011
 Melissa Gardiner                                       +44 (0)7757 697357

 

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
(https://investors.genedrive.com/s/efea03)

 

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) )

 

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company
focused on rapid, point-of-care diagnostic tests to guide safe and effective
drug prescription in emergency and acute care settings.

 

genedrive's proprietary technology platform enables clinicians to prescribe
safer and more effective therapies based on a patient's genetic profile,
supporting improved outcomes while reducing pressure on healthcare systems,
lowering downstream healthcare costs through the prevention of avoidable
complications and earlier, more effective intervention

 

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical
use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not
respond to the current standard of care, Clopidogrel, used to reduce risk of
secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent
antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment
decisions within actionable timeframes at the point of care.

 

Headquartered in Manchester, genedrive is focused on scaling UK-developed
precision diagnostics within routine care and leveraging real-world evidence
to support broader international adoption and commercial growth.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFIREDIAFIR



            Copyright 2019 Regulatory News Service, all rights reserved